Switch to:
More From Other Websites
These are the most profitable Nasdaq biotech companies Feb 27 2015
Gilead Sciences: 'HIV Succession Plan Coming Into Focus' Feb 27 2015
ImmunoVaccine Up 24% On Deal With Gilead Sciences Feb 27 2015
Mylan Signs Exclusive Agreement with Gilead Sciences to Distribute Sovaldi® and Harvoni® in India Feb 27 2015
Who Might Buy Puma Biotechnology? Feb 27 2015
Gilead Announces Phase 3 Results for Investigational Once-Daily Single Tablet HIV Regimen Containing... Feb 26 2015
Gilead Announces Phase 3 Results for Investigational Once-Daily Single Tablet HIV Regimen Containing... Feb 26 2015
Bristol-Myers: Drug combo cured hepatitis C in 97% with HIV Feb 26 2015
Gilead Announces SVR12 Rates From Phase 3 Study Evaluating Harvoni® for the Treatment of Chronic... Feb 26 2015
Health Care Stocks Flexing Their Muscle Feb 26 2015
How Gilead Avoids Billions in U.S. Taxes on Its $1,000-a-Pill Drug Feb 26 2015
Gilead dodges billions in taxes as money rolls in from hepatitis C drugs Feb 26 2015
Bristol hep C drug helps cure 97 pct of HIV coinfected patients-study Feb 26 2015
Gilead Announces SVR12 Rates From Phase 3 Study Evaluating Harvoni® for the Treatment of Chronic... Feb 26 2015
Omega Advisors opens a new position in Gilead Sciences Feb 26 2015
Biotech Making A Comeback - Here Is One Stock to Watch Feb 26 2015
Gilead Sciences: Despite Dividend, Still Room For Growth Feb 26 2015
Gilead Announces Preclinical Data for an Investigational TLR7 Agonist in SIV-Infected, Virally... Feb 25 2015
Gilead Announces Preclinical Data for an Investigational TLR7 Agonist in SIV-Infected, Virally... Feb 25 2015
Is A Renaissance In Surging Biotechs Underway? Feb 25 2015


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK